Genenta Science S.p.A (GNTA) Total Non-Current Liabilities (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Total Non-Current Liabilities of $9.2 million for Q4 2025, up 3.91% sequentially from $8.9 million in Q2 2025, and up 3673.8% YoY from $244628.2 in Q4 2024.
Genenta Science S.p.A (GNTA) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Total Non-Current Liabilities for 6 years, with the latest figure at $9.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3673.8% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (up 3673.8% YoY) and the FY2025 annual result came in at $9.2 million, up 3673.8% from the prior year.
- Total Non-Current Liabilities climbed to $9.2 million in Q4 2025 per GNTA's latest filing, from $8.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $9.2 million in Q4 2025 and troughed at $35026.1 in Q4 2021.
- A 5-year average of $2.1 million and a median of $192861.2 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities grew 26.84% in 2024, then soared 3937.23% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $35026.1 in 2021, then surged by 238.41% to $118533.4 in 2022, then soared by 62.71% to $192861.2 in 2023, then advanced by 26.84% to $244628.2 in 2024, then soared by 3673.8% to $9.2 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.2 million, $8.9 million, and $244628.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | 9.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.23 Mn |
| Jun 30, 2025 | 8.88 Mn |
| Dec 31, 2024 | 244,628.20 |
| Jun 30, 2024 | 220,060.90 |
| Dec 31, 2023 | 192,861.15 |
| Jun 30, 2023 | 163,831.94 |
| Dec 31, 2022 | 118,533.36 |
| Jun 30, 2022 | 93,473.10 |
| Dec 31, 2021 | 35,026.10 |
| Dec 31, 2020 | 20,731.54 |